Limited Submission Opportunities
(Applications through UCSF Limited Submission Program)
- Pre-app deadline: May 29, 2023
Mallinckrodt Foundation Grant Program
Purpose: to support early stage investigators engaged in basic biomedical research that has the potential to significantly advance the understanding, diagnosis or treatment of disease.
- Pre-app deadline: June 5, 2023
Robert J. Kleberg Jr. and Helen C. Kleberg Foundation Medical Research Grant
Purpose: to fund highly innovative and groundbreaking proposals in both basic biological and applied research that will have the greatest impact on scientific knowledge and human health.
- Pre-app deadline: June 5, 2023
NSF BioFoundries to Enable Access to Infrastructure and Resources for Advancing Modern Biology and Biotechnology
Purpose: to support the establishment of BioFoundries that focus on the innovation pipeline and research, while ensuring broad access to the research resources, training, education, and outreach to catalyze our understanding of biological or bio-engineered systems and to support the design-build-test-learn pipeline for rapid translation of basic discoveries into applications.
- Pre-app deadline: June 19, 2023
The G. Harold & Leila Y. Mathers Foundation Grants Program
Purpose: to support basic science, ideally with potential translational applications. Fields of interest include but are not limited to immunology, microbiome, genomics, structural biology, cellular physiology, and neuroscience.
Intramural Funding Opportunities
- Deadline: June 5, 2023
Prostate Cancer Program 2023 Research Pilot Awards
The UCSF Prostate Cancer Program seeks to fund pilot projects in any area of prostate cancer research. All areas of prostate cancer research including computational, laboratory, translational, clinical, and population sciences are eligible. Please note that this is a call for primary research proposals, and the opportunity is not intended to support resource or infrastructure development.
- Deadline: June 9, 2023
2023-2024 UCSF-JMH Cancer Research Collaboration
The UCSF-John Muir Health partnership is requesting project proposals for clinical research collaborations between UCSF main campus faculty and partners at UCSF-JMH Cancer Center in Berkeley or JMH Concord/Walnut Creek. Funding is intended to support collaboration of UCSF affiliate and UCSF main campus oncologists in investigator-initiated research studies.
- Deadline: July 3, 2023
DHART SPORE Developmental Research Program
The Developmental Research Program (DRP) supports innovative pilot projects to advance the diagnosis and treatment of early stage tumors and advanced cancers characterized by germline and somatic NF1 mutations through rigorous translational research in the areas of population science, therapeutics, and mechanisms of disease and by facilitating collaborative interactions between DRP-funded scientists and other SPORE investigators. [UCSF contact: Kevin Shannon, MD]
- Deadline: July 3, 2023
DHART SPORE Career Enhancement Program
The goals of the Career Enhancement Program are: (1) to attract outstanding early stage basic, translational and clinical investigators to the field of NF1-assocaited tumor research; (2) to assist in the career development of these early stage faculty; and, (3) to encourage collaborations between investigators that can lead to new ideas and directions in research related to tumors associated with NF1 mutations while also contributing to career development. [UCSF contact: Kevin Shannon, MD]
- Deadline: rolling submissions
University of California Hematologic Malignancies Consortium (UCHMC) RFA
The University of California Hematologic Malignancies Consortium is requesting submission of proposals within two potential areas of funding.
- RFP A: UCHMC funds for Junior Faculty and Trainee Competitive Seed Grants
- RFP B: UCHMC funds for Clinical Trials Support
- Deadline: June 7, 2023
Victoria's Secret Global Fund for Women's Cancers Career Development Award (in partnership with Pelotonia and AACR)
This program intends to fund innovative research projects in breast and gynecologic cancers and to invest in the next generation of female early-stage scientists domestically and globally. The aim of this award is to foster innovation in the understanding, prevention, interception, early detection, diagnosis, and treatment of breast and gynecologic cancers with the goal of eliminating cancer health disparities and improving patient outcomes.
- Deadline: June 21, 2023
AACR-Lung Cancer Initiative at Johnson & Johnson Stimulating Therapeutic Advances Through Research Training (START) Grant
We invite postdoctoral and clinical fellows to apply for the AACR-Lung Cancer Initiative at Johnson & Johnson START Grant. This unique three-year, $225,000 grant will provide the opportunity for training and research in both academia and industry, while allowing recipients to spend one year at a Johnson & Johnson facility. Applicants must be female or belong to one of the following underrepresented groups as per NIH guidelines, and the research proposal must have direct applicability to lung cancer. Potential applicants may reach out to the HDFCCC Office of DEIA for help with the application process (email [email protected]).
- Deadline: June 22, 2023
NCI-Cancer Research UK Cancer Grand Challenges
Cancer Grand Challenges aims to provide multiple rounds of funding for interdisciplinary research teams from around the world whose novel ideas offer the greatest potential to advance bold cancer research and improve outcomes for people affected by cancer. In this round, nine challenges were developed through a series of international workshops and an open call online that collected ideas from the cancer research community and people affected by cancer.
If you are a Cancer Center member who is interested in applying and receiving grant writing support, please contact Erin Bank.
Due June 30: Request for Information on Needs and Challenges in Obtaining and Testing Clinical-Grade RNA-based Cancer Vaccine Formulations to Support Translational and Clinical Research
The National Cancer Institute (NCI) is seeking broad input from persons and entities with interest, expertise, and experience in the development of novel RNA-based vaccines for cancer treatment and/or prevention. The NCI is seeking this input to inform future resource allocation and acquisition strategies that can accelerate the development, availability, and evaluation of such agents. Input is requested that will inform both pre-clinical and clinical testing of novel RNA-based cancer vaccines.
- Research With Activities Related to Diversity (ReWARD) (R01 Clinical Trial Optional)
- Supplement for your NCI grant: Apply for Administrative Supplements to Support Cancer Disparity Collaborative Research (PAR-22-114)
- NCI Research Specialist (Clinician Scientist) Award (R50 Clinical Trial Not Allowed)
- Modulating Human Microbiome Function to Enhance Immune Responses Against Cancer (R21 Clinical Trial Not Allowed)
To view NCI funding opportunities, search here